Clinical Studies with the Nal-Glu GnRH Antagonist
Because of the existence of anaphylactoid side effects following the subcutaneous (sc) injection of first generation antagonists of the [D-Arg6] class, there have been few clinical trials using GnRH antagonists in humans. These agents cause mast cell degranulation and histamine release [1, 2]. Recently, new classes of compounds have been designed and are available for phase 1 clinical trials.
KeywordsLuteal Phase GnRH Agonist Follicular Phase GnRH Antagonist Dominant Follicle
Unable to display preview. Download preview PDF.
- 3.Rivier, JE, Porter, J, Rivier, CL, Perrin, M, Hook, WA, Siraganian, RP and Vale, WW. New effective GnRH antagonists with minimal potency for histamine release in vitro. J med Chem, in pressGoogle Scholar
- 6.Fraser, HM (1987). LHRH antagonists and female reproductive function. In: Vickery, BH and Nestor, JJ Jr (eds.) “LHRH and its Analogs: Contraceptive and Therapeutic Applications. Part 2”. p.227. (Lancaster UK: MTP Press)Google Scholar
- 9.Fraser, HM and Baird, DT (1987). Clinical applications of LHRH analogues. J Clin Endocrinol Metab, 1, 43Google Scholar
- 12.Pavlou SN, Wakefield, GB and Kovacs, WJ (1987). LHRH antagonists in normal men. In: Vickery, BH and Nestor, JJ (eds.) “LHRH and its Analogs: Contraceptive and Therapeutic Applications. Part 2”. p.245. (Lancaster UK: MTP Press)Google Scholar